Centro Médico Teknon
Centro Médico Teknon
Espanha, Barcelona
Francesc Cobo Valien
27 anos de experiência
Clínica certificada :
| Turquia | Áustria | Espanha | |
| Transplante de medula óssea | de $27,500 | de $140,000 | de $130,000 |
| Transplante alogénico de medula óssea de dador relacionado | de $57,500 | de $150,000 | de $130,000 |
| Transplante alogénico de medula óssea de dador não relacionado | de $66,000 | de $180,000 | de $150,000 |
| Terapia com células T CAR | de $200,000 | de $350,000 | de $330,000 |
| Terapia biológica | de $5,500 | de $20,000 | de $15,000 |
A Bookimed não adiciona taxas extras aos preços de tratamento de Oncologia Hematológica. As tarifas vêm das listas oficiais das clínicas. O pagamento é feito diretamente na clínica na chegada ao país.
A Bookimed está comprometida com sua segurança. Trabalha apenas com instituições que mantêm altos padrões internacionais no tratamento de Oncologia Hematológica e têm as licenças necessárias para atender pacientes internacionais em todo o mundo.
A Bookimed oferece assistência gratuita de especialistas. Um coordenador médico pessoal apoia antes, durante e após o tratamento, solucionando problemas. Nunca está sozinho em sua jornada de tratamento de Oncologia Hematológica.
Dr. Jaume Mora Graupera is a pediatric oncologist specializing in the treatment of neuroblastomas, gliomas, Ewing's sarcomas, and Wilms' tumors. He is the Director of the Hematology Oncology Department and Developmental Tumors Laboratory at Sant Joan De Déu - Barcelona Children’s Hospital. He received his medical degree from the University of Barcelona, went on to complete specialty training in pediatrics and fellowships in pediatric hematology oncology and molecular pathology of pediatric cancer at Weill Cornell Medicine and Memorial Sloan Kettering Cancer Center in the USA. He has won multiple awards and is a member of various medical organizations.
Children's Hematologist. Specialist in bone marrow transplantation
Dr. Francesc Bosch is an expert in Chronic Lymphocytic Leukemia (CLL) and lymphomas. He leads research in the molecular causes and new treatments for CLL and other lymphoproliferative disorders.
He has published over 100 articles in leading journals, including The New England Journal of Medicine and Nature Medicine. Dr. Bosch oversees more than 80 clinical studies, from phase 1 to phase 3, and plays a key role in developing new drugs.
He is the Head of Hematology at Vall d’Hebron University Hospital and IOB Institute of Oncology. He also serves as president of GELLC and is a professor of hematology. His work has improved diagnosis and treatment for blood diseases.